Daniel Patrick O'Day
Chairman & CEO at Gilead Sciences Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Gilead Sciences Inc., 3 years.
Gilead Sciences Inc.
Director · Chairman & CEO
Chief executive roles
Gilead Sciences Inc.
· Chairman & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2024 | Gilead Sciences Inc. | Option exercise | +10,295 | — | — |
| Jun 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −4,693 | $65.25 | $306,218 |
| Mar 10, 2024 | Gilead Sciences Inc. | Option exercise | +10,800 | — | — |
| Mar 10, 2024 | Gilead Sciences Inc. | Option exercise | +19,140 | — | — |
| Mar 10, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −13,782 | $75.12 | $1,035,304 |
| Jan 31, 2024 | Gilead Sciences Inc. | Grant or award | +50,870 | — | — |
| Jan 31, 2024 | Gilead Sciences Inc. | Grant or award | +179,877 | — | — |
| Jan 31, 2024 | Gilead Sciences Inc. | Shares withheld for tax | −79,335 | $78.26 | $6,208,757 |
| Dec 10, 2023 | Gilead Sciences Inc. | Option exercise | +7,347 | — | — |
| Dec 10, 2023 | Gilead Sciences Inc. | Shares withheld for tax | −3,341 | $79.02 | $264,006 |
| Sep 10, 2023 | Gilead Sciences Inc. | Option exercise | +7,348 | — | — |
| Sep 10, 2023 | Gilead Sciences Inc. | Shares withheld for tax | −3,366 | $76.00 | $255,816 |
| Jun 10, 2023 | Gilead Sciences Inc. | Option exercise | +7,346 | — | — |
| Jun 10, 2023 | Gilead Sciences Inc. | Shares withheld for tax | −3,409 | $78.12 | $266,311 |
| Mar 10, 2023 | Gilead Sciences Inc. | Option exercise | +19,488 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.